Archive for July, 2021
- The pay-per-view match was streamed on Showtime as well as several forms of post-fight media including ESPN, Sky Sports and Barstool
- TryTAAT landing page received new visitors from more than 30 different countries
- TAAT logo displayed to millions of global viewers who watched the match, as well as post-fight coverage
Interest in TAAT(TM), the nicotine-free and tobacco-free smoking product offered by TAAT(TM) Global Alternatives (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP2) has risen sharply following the company’s sponsorship of the June 6, 2021, boxing match between world champion boxer Floy Mayweather and internet personality Logan Paul. The pay-per-view match, was streamed on Showtime as well as several forms of post-fight media including ESPN, Sky Sports and Barstool.
The weekend of the fight, the company’s TryTAAT landing page received new visitors from approximately 30 different countries (https://ibn.fm/uup0R). More than 14% of those who visited the page, which offers a complimentary pack of TAAT Original, Smooth, or Menthol requested a sample, with the total number of sample requests for the weekend reaching as much as 15.5 times higher than weekends in May 2021. The company also reported additional interest on Instagram, where the TAATGlobal and TryTAAT channels combined saw a 200% increase in followings.
Although total numbers of those who viewed the fight and after-fight media hasn’t been released, TAAT reported that its logo was displayed to millions of global viewers who watched the match, as well as post-fight coverage. TAAT’s sponsorship called for between six and eight of Mayweather’s entourage personnel to wear a baseball hat with the TAAT logo clearly visible during their entry to the arena and approach towards the boxing ring (https://ibn.fm/JTYNG).
In addition, Mayweather posted a video introducing TAAT on his Instagram profile in both timeline and story posts; Mayweather has 26.3 million followers. Paul also posted footage from the match, and that footage shows the TAAT as well; Pauls has 20.1 million followers on his Instagram account.
“As an athlete, naturally, I avoid anything that limits my ability to perform, so I can’t speak for smokers,” said Mayweather about the sponsorship. “But any addictive product that impacts the lungs is going to limit your ability to be the best version of you. I don’t judge you for your decision to smoke, but don’t claim to be the best version of yourself when you turn to nicotine and addictive substances over healthy alternatives.”
TAAT Global Alternatives has developed TAAT, a tobacco-free and nicotine-free alternative to traditional cigarettes available in Original, Smooth and Menthol varieties. TAAT’s base material is Beyond Tobacco, a proprietary blend that undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco. Under executive leadership with Big Tobacco pedigree, TAAT was launched first in the United States in Q4 2020 as the company seeks to position itself in the $814 billion global tobacco industry.
For more information, visit the company’s websites at www.TryTAAT.com and www.TAATGlobal.com.
NOTE TO INVESTORS: The latest news and updates relating to TOBAF are available in the company’s newsroom at https://ibn.fm/TOBAF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
Red White & Bloom (CSE: RWB) (OTCQX: RWBYF), a multistate cannabis operator and house of premium brands, has reported fourth quarter and full year 2020 financial results and company highlights. The report noted that Q4 2020 adjusted sales totaled C$28.6 million, an increase of 290% over the third quarter, with fourth quarter 2020 revenue reaching C$15.7 million, an increase of 158% over the third quarter. Finally, full year 2020 adjusted sales topped more than $37.8 million with revenue coming in at $23.3 million. In addition, the announcement noted that RWB closed two significant acquisitions, completed its go-public transaction and established its first THC operations and brands, as well as raised more than $100 million to support expansion and operation efforts. In addition, Red White & Bloom announced that it has scheduled a conference call and audio webcast to provide an overview of the company’s 2020 and Q1 2021 operating results and 2021 outlook; the webcast will also include a Q&A session. Anyone interested can participate by calling (877) 705-6006 toll-free or (201) 689-8557 for international. “We set out at the beginning of 2020 with a three-year plan for our success,” said Red White & Bloom CEO and chair Brad Rogers in the press release. “Our strategy was to establish a foundation for the overall company and identify the core states to operate in and a plan to scale in those states. We have set the foundation for our core states including Michigan, Illinois, Florida and California. In 2021 we look to expand through an asset light approach in other states, such as Arizona, and complete the integration of our M&A targets while gaining operational synergies from all we have accomplished over the last 18 months. For the balance of 2021 and throughout 2022, the company will focus on the continued growth of our topline revenue and bottom-line results through expansion of our house of brands that continue to gain momentum, fortification of our vertically integrated businesses, and the synergies from our M&A success.”
To view the webcast, visit https://ibn.fm/UWAST
To view the full press release, visit https://ibn.fm/2HGkF
About Red White & Bloom Brands Inc.
Red White & Bloom Brands is positioning itself to be one of the top-three, multistate cannabis operators active in the U.S. legal cannabis and hemp sector. RWB is predominantly focusing its investments on major U.S. markets, including Michigan, Illinois, Massachusetts, Arizona and California, with respect to cannabis, as well as the United States and internationally for hemp-based CBD products. For more information about the company, please visit www.RedWhiteBloom.com.
NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at http://ibn.fm/RWBYF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Kaival Brands (OTCQB: KAVLD), the exclusive global distributor of products manufactured by Bidi(R) Vapor LLC, has announced that the Bidi(TM) Pouch will begin production again after being delayed because of COVID-19 restrictions. The company anticipates that the Bidi Pouch, which provides a proprietary tobacco-free nicotine formulation packed in an easy-to-go plastic can, will be launched in September. According to the announcement, production of the pouch has been moved in-house to prevent future delays and bottlenecks. Kaival Brands notes that the nicotine pouch spaces present a significant market opportunity, with a recent study showing an increase in unit sales over the past year of 59.9% in convenience stores located in the United States; MarketResearch.com has projected that the global nicotine pouches market will total an estimated $32.8 billion by the end of 2026. In addition to its announcement about Bidi Pouches, Kaival noted that the company recently completed a reverse split and is temporarily trading under the symbol KAVLD until its anticipated listing on the Nasdaq exchange. “I am pleased to confirm that we expect to take delivery of the pouch-manufacturing machines to our warehouse the end of August and anticipate beginning production in September with our first run expected to yield up to 500,000 cans,” said Kaival Brands founder and CEO Niraj Patel in the press release. “We are excited to launch distribution of the Bidi Pouch and have been working behind the scenes during COVID-based delays to secure initial distribution. To that extent, we are proud to announce that 8,000 points of distribution have been secured and are ready to receive our product.”
To view the full press release, visit https://ibn.fm/7Pt51
About Kaival Brands Innovations Group Inc.
Based in Grant, Florida, Kaival Brands is a company focused on growing and incubating innovative and profitable products into mature and dominant brands in their respective markets. The company’s vision is to develop internally, acquire, own or exclusively distribute these innovative products and grow each into dominant market-share brands with superior quality and recognizable innovation. Kaival Brands is the exclusive global distributor of all products manufactured by Bidi Vapor. For more information about the company, visit www.KaivalBrands.com.
NOTE TO INVESTORS: The latest news and updates relating to KAVL are available in the company’s newsroom at http://ibn.fm/KAVL
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
- Infobird continues to invest in AI resources, research, and development to provide its customers with SaaS products that come integrated with AI capabilities
- It plans to capitalize on the growing AI wave and an industry that is projected to grow to US$24.6 billion by 2025
- Infobird plans to capitalize on its understanding of AI, its big data technology, and its brand equity to grow its market share and penetrate various industries within the Chinese market
- Its primary focus currently is on intelligent quality inspection, a system of RPA based on big data for intelligent and automatic quality inspection of customer service
The popularity of Artificial Intelligence (“AI”) is growing. Its influence on processes and business cannot be ignored. Back in 2019, the retail automation market was valued at US$12.45 billion and is expected to grow to US$24.6 billion by 2025 (https://ibn.fm/E4lIR). This growth will largely be fueled by the growing development in natural language processing and the monetary incentives that this automation offers. Infobird (NASDAQ: IFBD) has made incredible strides in its natural language processing technology and understanding of the market. It plans on capitalizing on these strides and the ongoing AI wave to differentiate itself from its competitors and offer value to its clients.
Infobird is currently at the forefront of pushing for intelligent quality inspection. This is a system of robotic process automation (“RPA”) based on big data, AI, and other technologies that allow big enterprises to achieve intelligent and automatic quality inspection of customer service. This is a track of the whole intelligent product that can automatically keep engagement between companies and their client. The business value based on this is large. It can not only ensure higher policy or business compliance, but also empower the management team to better standardize the services they provide to the clients, which is key to large customer service or sales centers.
In addition to these technologies, the company is committed to customizing exclusive models for particular fields to maximize the recognition effect, thereby proving more beneficial to customers.
Infobird is a software-as-a-service (“SaaS”) provider of AI-powered customer engagement solutions specifically for the Chinese market. With its self-developed cloud computing structure, machine learning, AI, and patented Voice Over Internet Protocol (VoIP) application technologies, the company has appealed to its customers a lot more and offered a unique value proposition that not many other companies present in the market today (https://ibn.fm/iTJcj).
Infobird’s foundations are on technology, hence its commitment to AI. The company also has 70 Intellectual Property (“IP”) rights developed under its cloud-native architecture and AI technologies.
Since it was founded in 2001, it has been committed to improving its services and leveraging technology. Initially, the company joined the call center industry, primarily as a middleware manufacturer. However, following years of technical accumulation, it is now able to offer AI-powered call centers and was able to bring in revenues of over US$14.5 million back in 2020 (https://ibn.fm/HBLlt).
The Chinese SaaS industry is growing at a tremendous pace, posting an increase in value from US$33 billion back in 2019 to US$47 billion in 2020. In 2022, it is expected to be valued at US$69 billion (https://ibn.fm/W2qRT). Infobird plans on making the most out of this market and capitalizing on its growth. Its years of experience, innovations, and achievements so far position it as an industry leader. Also, given its understanding of AI, its big data technology, and its brand equity, the company is projected to grow and even penetrate further into other sectors that include but are not limited to public services, education, healthcare, transportation, and retail sectors.
Infobird’s investment in AI resources, research, and development allows it to provide its customers with SaaS products that come integrated with AI capabilities. The company fully understands the value and potential of AI, hence its commitment to invest in its products and services and continue innovating to best help small and medium-sized enterprises in China.
For more information, visit the company’s website at www.Infobird.com/en/index.html.
NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at https://ibn.fm/IFBD
About ChineseWire
ChineseWire (CW) is a specialized communications platform focused on promising China-based companies that are listed in North America. As one of 40+ brands within the InvestorBrandNetwork (“IBN”), CW provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution to IBN’s millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, CW is uniquely positioned to best serve private and public Chinese companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CW brings its clients unparalleled visibility, recognition and brand awareness. CW is where news, content and information converge.
For more information, please visit https://www.ChineseWire.com
Please see full terms of use and disclaimers on the ChineseWire website applicable to all content provided by CW, wherever published or re-published: http://IBN.fm/Disclaimer
ChineseWire (CW)
Los Angeles, California
www.ChineseWire.com
310.299.1717 Office
Editor@ChineseWire.com
ChineseWire is part of the InvestorBrandNetwork.
As several countries and automakers move toward electrification, most of the focus has been placed on passenger vehicles. After all, these types of cars make up the majority of the vehicles on the world’s roads and are responsible for more than 40% of global carbon emissions from transportation. As such, most automakers have focused on building electric passenger vehicles, and governments keen on electrification have been working to push electric vehicle (“EV”) adoption among the masses.
However, a new study has found that electrifying the commercial truck segment could have even bigger benefits. Like the trains of old, diesel trucks have revolutionized long-distance shipping, facilitating the transport of 72% of America’s freight across vast distances. In 2019, the U.S. alone had almost 4 million Class 8 trucks operating on its roads, says the American Trucking Association, with most of them running on diesel. Globally, commercial trucks account for nearly one-third of carbon emissions from vehicles, despite making up just a small fraction of the vehicles on the road.
By targeting and electrifying the long-haul trucking segment, researchers from the University of California and the DOE’s Lawrence Berkeley National Laboratory believe the United States could see a major reduction in carbon emissions. They analyzed the total cost of ownership (“TCO”) of an electric long-haul truck, assuming it had a 375-mile range and was using current battery pack prices. By comparing their results to the TCO of a diesel truck, they found that an electric model would cost 13% less per mile, saving fleet managers up to $200,000 over the lifetime of an electric long-haul truck.
By forecasting reducing battery costs over the coming years and other improvements on battery and EV technology, the researchers reported that by 2030, the TCO of electric trucks would be 50% lower. On top of saving companies and municipalities hundreds of thousands of dollars, electrifying commercial trucks would help these entities cut their emissions by a wide margin, enabling them to meet increasingly strict emissions standards. Nikit Abhyankar, a research scientist at Berkeley Lab and one of the study’s authors, says policies for EV adoption and charging infrastructure incentives, cost-effective electricity pricing, and sales mandates, among others things, will be instrumental in electrifying the commercial long-haul truck segment.
Some established automakers and EV makers have already spotted this opportunity, with companies such as Tesla, Daimler and Volvo running electric truck pilots. The Tesla Semi is currently being tested on state highways, and PepsiCo has said that it expects Tesla to deliver 15 of its Semi electric trucks by the end of the year. Additionally, Walmart Canada tripled its order to 130 Tesla Semis.
Lead author of the study and Berkeley Lab staff scientist Amol Phadke says that if the country can steadily replace diesel-powered, heavy-duty vehicles with electric alternatives, the U.S. can significantly reduce particulate and greenhouse gas emissions from the transportation industry.
As companies such as Ideanomics Inc. (NASDAQ: IDEX) press ahead with their mission of facilitating the switch to commercial electric vehicles, the chances that fleets will go electric are high over the coming years.
NOTE TO INVESTORS: The latest news and updates relating to Ideanomics Inc. (NASDAQ: IDEX) are available in the company’s newsroom at https://ibn.fm/IDEX
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
A new study has found that low doses of ketamine and psilocybin can boost attention and intensify motivation associated with food in low-performing rodents. Guy Higgins, lead author of the study and CEO of InterVivo Solutions, the company that carried out the study, stated that interest in the pharmacological effects of low doses of NMDA antagonists is what led the research team to study psilocybin and ketamine.
Anecdotal reports on micro-dosing psychedelics indicate that the substances improve cognitive function and mood in humans. However, very few appropriately controlled trials have been conducted in this field. Higgins explained that the objective of their study was to define the effects of these psychedelics in rodents using behavioral tests, noting that preclinical research into micro-dosing psychedelics was scant.
The study, which was placebo controlled, looked into the effects of different small doses of psilocybin and ketamine in rodent models. The scientists utilized the 5-choice task, which is a behavioral measure of impulsivity and attention, and the progressive ratio task, which is a behavioral measure of motivation and reward processing, to repeatedly test the rodents before beginning their experiment, in order to categorize them into two groups: the high and low performers.
The researchers discovered that low doses of both ketamine and psilocybin were linked to increases in impulsive action, attentional accuracy and task motivation in rodents classified as low performers.
Higgins explained that there existed no actual scientific consensus on what microdosing on psychedelics actually meant, as there are no stipulated dosing schedules or plasma levels. This, he continued, was why they defined behavioral effects and plasma exposures for both psilocybin and ketamine in their study and conducted tests relevant to depression that could be translated to humans. He noted that this could provide a point of reference for future research and facilitate their research in controlled human trials.
While microdosing on psychedelics has shown potential in improving mental health conditions, the majority of evidence is presently based on self reports recollected by individuals, which are prone to bias and errors. Furthermore, Higgins stated that having a scientific rationale of mechanism would be beneficial to the microdosing field, asserting that safety issues would also need to be addressed. This, he explained, was because low doses of psilocybin and ketamine would be administered more frequently, adding that the safety profile of the drugs could vary from the macro-dose range.
The study was reported in “Frontiers in Pharmacology” and was conducted by Higgins, Edward M. Sellers, Ines DeLannoy, Lilia Magomedova, Julia Izhakova, Sandy Thevarkunnel, Leo B. Silenieks, Cam MacMillan, Matt Brown and Nicole K. Carroll.
This study evaluating how ketamine and psilocybin affect attention and motivation isn’t the only study analyzing these substances. Several companies, including Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF), are looking to develop therapeutic formulations from psychedelics in order to take mental health care to the next level.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
CNS Pharmaceuticals (NASDAQ: CNSP), a pharmaceutical company enthusiastically pursuing enrollment of about 243 brain cancer patients in a clinical trial designed to analyze the efficacy and safety of its lead drug candidate, was selected to be added to the Russell 2000 Index effective June 25. A subset of the Russell 3000 Index, the Russell 2000 Index is a measure of the performance of the small-cap segment of the U.S. equity market. Per CNS Pharmaceuticals CEO John Climaco, quoted in a recent article, the company was pleased to meet this noteworthy milestone. He said, “As our team continues to drive our clinical program forward for the treatment of glioblastoma multiforme (‘GBM’), we believe this inclusion well-positions us to drive market awareness. . . We look forward to leveraging the access and positioning this inclusion brings to unlock additional value.”
To view the full article, visit: https://ibn.fm/2DOXO
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Additionally, the company is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian and lymphomas. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at http://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, is a recognized leading innovative player in the brain monitoring space. The company continues to be at the forefront of what is next in neurology technology. In a Tech Times feature, Brain Scientific’s Marketing Director Irina Nazarova outlined key brain monitoring trends to watch in 2021, including the fact that brain monitoring is becoming as popular and widespread as monitoring pulse or heart rate. Several potential applications have swelled, and EEG monitoring is no longer a preserve of clinicians and expert neuroscientific researchers. A recent article reads, “Exciting new opportunities are potentially in front of EEG technology. EEG-based products go beyond the medical space and are on their way to penetrate new sectors and find more uses. Brain Scientific is committed to remaining a key innovative leader in what could potentially be a rapidly growing market over the next years.”
To view the full article, visit: https://ibn.fm/LojNW
About Brain Scientific Inc.
Brain Scientific is a commercial-stage healthcare company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices, or for investor relations, visit www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at http://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Electric vehicles (“EVs”) still make a minuscule percentage of new vehicles sold every year, but governments all around the world are trying to sell EVs to their citizens. If governments are to succeed in this crucial goal, they should look to Liuzhou, a city in China that has been dubbed the country’s electric car capital.
China is the largest EV market in the world, with its residents buying more EVs compared to other developed nations. The southern Chinese city of Liuzhou has done quite a lot to fill its streets with electric vehicles; their actions could be applied to other cities and countries as well. Last year, a whopping 30% of the cars sold in this city were electric, reports Guangzhou-based consulting firm WAYS Information Technology. This makes the city of 4 million second only to Norwegian capital Oslo, where up to 50% of new vehicles sold were electric.
How did Liuzhou achieve this feat? The city has partnered with SAIC-GM-Wulling Automobile Co, which developed the Baojun E100, a tiny, affordable EV that has even given Tesla a run for its money. On top of that, it has rolled out several incentives including free parking and extensive test drives, and the city has installed tens of thousands of charging points to encourage EV adoption among its residents.
To expose its citizens to electric vehicles, the city partnered with SAIC-GM-Wulling to carry out a 10-month free test drive campaign for EVs in 2017. So popular was the program that more than 15,000 people took the Baojun E100 for a test drive, booking all available slots within just minutes and providing the automaker with tons of feedback. Eventually, 70% of the test drivers were so impressed they walked away with a new EV.
SAIC-GM-Wulling used the feedback the test drivers provided to tailor the Baojun E100 to the city residents’ needs and daily driving habits. The EV itself is almost half the length of a Tesla Model X, with its size coming with plenty of advantages, and it sells for only $5,000. Thanks to the EV’s small size, the city has been able to create 15,000 additional parking spots, taking advantage of previously unusable tracts of land that couldn’t fit conventionally sized vehicles.
Baojun E100 drivers also enjoy unlimited free parking at EV parking lots, and they pay just 0.1 yuan or 15 cents per kilometer to charge. In regular parking lots, they can park for up to two hours for free. Due to the size of the vehicles, EV owners can also charge using household outlets with ease, and consequently Wulling has been able to install a whopping 30,000 charging outlets at a fraction of the usual cost throughout the city.
While Liuzhou has definitely received plenty of state support, which may not be possible in other countries, embracing small, lightweight EVs has been a game changer for the city. Providing heavily subsidized and in many cases free parking as well as tens of thousands of charging points has made using EVs on a daily basis easy and stress free. Cities and countries that want to boost EV adoption among their own citizens would do well to learn from Liuzhou.
The reality is that governments cannot on their own take every measure necessary to popularize electric vehicles, and that is why companies such as Ideanomics Inc. (NASDAQ: IDEX) that step up to boost EV adoption should be applauded.
NOTE TO INVESTORS: The latest news and updates relating to Ideanomics Inc. (NASDAQ: IDEX) are available in the company’s newsroom at https://ibn.fm/IDEX
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
- XPhyto partners with AGORA t to grow its brand and overall market share
- The agreement entails shares issued to AGORA on August 21, 2021 and December 31, 2021 at a price of $2.12 per share, subject to a hold period that ends on October 18, 2021
- AGORA is known for its online marketing, conferences, broadcasting and investor relations services
- Its clients include CardioComm Solutions, Good Life Networks, Northern Sphere, Grizzly Discoveries and IntellaEquity Inc., among others
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) just announced that it is following through with its advertising agreement with AGORA Internet Relations Corp (“AGORA”) that dates back to December 1, 2020.
The agreement entails shares issued to AGORA on August 21, 2021 and December 31, 2021 at a price of $2.12 per share, subject to a hold period that ends on October 18, 2021 with respect to the various applicable securities legislation. With this move, AGORA now holds 20,549 common shares of XPhyto, equivalent to 0.03% of the issued and outstanding common shares (https://ibn.fm/GVoHm).
AGORA is known for its online marketing, conferences, broadcasting and investor relations services for the global market. With its online community, AGORA is able to help investors and small companies to not only discuss but also discover small cap stocks and investment opportunities (https://ibn.fm/BgDHx). Its client list is constantly growing and is currently made up of companies such CardioComm Solutions, Good Life Networks, Northern Sphere, Grizzly Discoveries and IntellaEquity Inc., among others (https://ibn.fm/cuUyv). XPhyto plans on capitalizing on the experience that AGORA has by working with the other clients and leveraging on this to grow its brand and overall market share.
XPhyto is a life sciences technology accelerator, focusing on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. Its biggest achievement so far has been its rapid COVID-19 PCR test kit that reduces test turnaround times to less than 30 minutes (https://ibn.fm/KELop). The company has operations in Europe and North America, with an operational focus in Germany.
This partnership with AGORA has the potential to push the XPhyto brand even further, allowing it to appeal to more customers and fulfil its agenda for growth and commercialization for the European market.
For more information, visit the company’s website at www.XPhyto.com.
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
TAAT(TM) Global Alternatives (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) has announced that work on its new facilities, which are located in Las Vegas and designed to ensure the company has ample capacity to meet forecast demand, is moving forward. Specifically, the company stated that all processing equipment, including mixers, shredders and conveyor belts, has been successfully moved into the new manufacturing facility with plans for additional machinery, including finishing equipment, to arrive in the coming weeks. Based on those dates, the company noted that the new manufacturing facility should be operational in August 2021. The announcement also noted that the new facilities will considerably increase TAAT’s total operating space and provide room for the creation of new internal departments such as digital content production and event management. The company’s new warehouse facility can store up to 400,000 pounds of TAAT’s Beyond Tobacco(TM) base material in a humidity-controlled space. Finally, the fulfillment station at the new warehouse is more than 200% larger than TAAT’s current fulfillment space. The announcement noted that TAAT management is also evaluating technologies and solutions that could further optimize in-house order fulfillment with this additional space. “Expanding and upgrading the company’s operating facilities after barely three calendar quarters of selling TAAT(TM) at retail is an excellent indicator of our progress in my opinion,” said TAAT CEO Setti Coscarella in the press release. “At this time last year, I was still at Philip Morris International, and TAAT was still offering ‘test’ iterations of the product to smokers aged 21+ in Nevada and California. Now that we have tobacco wholesalers in multiple markets distributing TAAT to more than 300 retail stores in addition to an e-commerce pipeline with clientele in 37 U.S. states, I believe it goes without saying that we could not continue operating out of the same facility if we’re looking to continue scaling our business. Everything is looking great so far, and we are excited to be making this expansion official in August, giving us the room we need to grow as an emerging player in the tobacco industry.”
To view the full press release, visit https://ibn.fm/aFC1r
About TAAT Global Alternatives Inc.
TAAT Global Alternatives has developed TAAT, which is a tobacco-free and nicotine-free alternative to traditional cigarettes offered in Original, Smooth and Menthol varieties. TAAT’s base material is Beyond Tobacco, a proprietary blend that undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco. Under executive leadership with Big Tobacco pedigree, TAAT was launched first in the United States in Q4 2020 as the company seeks to position itself in the $814 billion global tobacco industry. For more information, please visit www.TAATGlobal.com.
NOTE TO INVESTORS: The latest news and updates relating to TOBAF are available in the company’s newsroom at http://ibn.fm/TOBAF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Splash Beverage (NYSE American: SBEV), a portfolio company of leading beverage brands, including SALT Citrus flavored tequila, released its forward-looking revenue guidance for Q3 and Q4 2021 fiscal year as well as fiscal year 2021 results. The company is currently in its third quarter, and the announcement noted that it anticipates revenue of $4.14 million, which would be an increase of 34% sequentially and 310% over the same quarter in 2020. Splash also released its projected FY Q4 2021 results, which should reach an estimated $5.78 million, a sequential quarterly increase of 39% and a comparative quarterly increase of 366%. Finally, the company also reported that it anticipates year-end guidance for total revenues to reach $15.97 million, a year-over-year increase of 436%. The company also noted key business highlights. Those highlights include uplisting SBEV stock to the NYSE/American exchange, entering at least seven significant distribution agreements with leading independent U.S. distributors and beginning operations on its initial acquisition of Copa di Vino. In addition, the company secured a distribution deal with American Software Capital to distribute all its brands in China, which represents a combined market opportunity of more than $64 billion, and announced that its Qplash platform will integrate all Splash brands to expand its national market presence. “We are seeing broad market penetration of all our brands across U.S. markets and expect similar traction in our overseas distribution agreements, making us comfortable to provide initial revenue guidance heading into the back half of this year,” said Splash Beverage president and CEO William Meissner in the press release. “We are particularly encouraged by the current 71% increase in Pulpoloco sales compared to last year, as well as significant growth and positive consumer response to Copa Di Vino, TapouT hydrating sports drink, and flavored SALT 100% agave tequila brands. . . . Heading into the back half of this year, which is usually a seasonally strong period for beverage and spirits sales, we expect to see an acceleration of brand development across the board. We believe that both SALT tequila and Copa Di Vino are positioned for at least double-digit percentage growth, and with TapouT being part owned by the WWE, we believe the market penetration for that product can lead to exponential growth on a national scale.”
To view the full press release, visit https://ibn.fm/INLgI
About Splash Beverage Group Inc.
Splash Beverage Groupspecializes in manufacturing, distribution, sales and marketing of various beverages across multiple channels. SBEV operates in both the nonalcoholic and alcoholic beverage segments, which the company believes leverages efficiencies and dilutes risk. SBEV believes its business model is unique because it only develops and accelerates brands it perceives to have highly visible pre-existing brand awareness or pure category innovation. For more information about the company, please visit www.SplashBeverageGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to SBEV are available in the company’s newsroom at http://ibn.fm/SBEV
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
While America’s state legal cannabis industry has grown steadily, creating hundreds of thousands of new jobs and generating billions in revenue, federal law still classifies cannabis as a Schedule I controlled substance. President Joseph Biden has said that, while he supports medical marijuana and giving states the ability to decide how to treat cannabis themselves, he is not behind federal legalization of recreational cannabis. Even though Senate Majority Leader Chuck Schumer has said that he is working on federal cannabis legislation and will advance it with or without the president’s support, the Democrats’ window for passing federal cannabis reform is closing.
Consequently, a bipartisan coalition of advocacy groups and businesses has issued a white paper urging the federal government to legalize recreational cannabis. The 14-page white paper, published last week by the Cannabis Freedom Alliance, expressed the group’s frustration with President Biden’s stance on cannabis, which was recently witnessed after sprinter Sha’Carri Richardson was excluded from the U.S. Olympics team for using cannabis. Richardson, who reportedly used cannabis in Oregon, which allows adult use, was expelled from the team when her drug tests came back positive for cannabis.
Regarding the U.S. Anti-Doping Agency’s decision to invalidate the results of her 100 meter run at the Olympic trials and suspend Richardson for 30 days, Biden says “rules are rules,” adding that the question of the rules being changed is an altogether different subject. However, the inconsistencies between state and federal law, points out executive director of the Drug Policy Alliance Kassandra Frederique, leave people such as Richardson “stuck in the middle,” having to decipher unclear rules and often suffering the consequences for life.
The Cannabis Freedom Alliance advises removing marijuana from the Controlled Substances Act to resolve the issues caused by the inconsistencies between state and federal cannabis law. According to the white paper, the alliance hopes to establish a comprehensive regulatory structure that focuses on research, innovation and public safety; give the victims of the drug war, especially those with nonviolent cannabis related charges, a leg up in the legal market; and ensure the market has minimal barriers to entry, allowing both entrepreneurs and large companies an equal chance.
The coalition would also like to keep the tax burden on the cannabis market low to prevent customers from going to the illicit market for lower-priced products. This would deal the criminal enterprises behind the black market a major financial blow while ensuring the growth of the legal industry. Formed in April, the Cannabis Freedom Alliance includes the Global Alliance of Cannabis Commerce, Law Enforcement Action Partnership, Libertarian think tank Reason Foundation, criminal justice reform initiative Mission Green and Americans for Prosperity, which is backed by the Koch family.
The voices calling for federal marijuana policy reform are growing louder, and any reforms in that direction would greatly ease the regulatory and legal tightrope that cannabis sector players, such as Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF), have to walk as they adhere to enabling laws at state level while being aware of the prohibition at the federal level.
NOTE TO INVESTORS: The latest news and updates relating to Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) are available in the company’s newsroom at https://cnw.fm/RWBYF
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries, was featured in a recent episode of the Stock Day podcast. In the podcast, PBIO president and CEO Richard Schumacher the company’s recent nanoemulsion achievements with podcast host Everett Jolly. During the interview, Schumacher stated that the company recently transformed the potent antioxidant astaxanthin into a water-soluble compound, noting that astaxanthin, the most powerful nutritional antioxidant known to humans, is in short supply and is not easy to obtain. The substance is extracted from algae in an oil, and because it is an oil, the human body has problems absorbing it. “The solution lies in finding ways to get them to mix and stay in solution,” said Pressure BioSciences president and CEO Richard Schumacher in the press release. “But even conventional emulsions and microemulsions of oils in water still allow vast numbers of the oil molecules to hide in the interior of the droplets, where they cannot be absorbed by our bodies. However, using Pressure BioSciences’ new high-pressure driven Ultra Sheer Technology(TM) platform, we were able to consistently and reproducibly nanoemulsify it into droplets so small that the oil becomes essentially water soluble, and the oily molecules are effectively all exposed at the surface of the oil droplet for easy access and absorption by our bodies.”
To view the full podcast, visit https://ibn.fm/WQrrr
To view the full press release, visit https://ibn.fm/Ttnd7
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) (“PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). The company’s primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of the company’s pressure-based technologies in the following areas: (1) the use of PBIO’s recently acquired, patented technology from BaroFold Inc. to allow entry into the biopharma contract services sector and (2) the use of PBIO’s recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to prepare higher-quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information about the company, visit www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
- PlantX Life recently launched as a seller on both Walmart Canada Marketplace and Hudson’s Bay Marketplace
- The launches appear to be leveraging the changes and trends brought about by the COVID-19 pandemic
- In addition, the agreements are part of PlantX’s growth strategy
- The company will offer thousands of its products on both platforms
As the COVID-19 pandemic upended multiple aspects of life in Canada, it did not spare the retail industry. Here, it forced Canadians to rethink how, where and when they shop, with the paramount consideration in their decision-making process being their personal and family health and safety. Shopping was no longer about what was trendy, cheap or convenient, but how safe it was. This shift instigated a dramatic drop in the number of in-store visits, even for groceries, with shoppers instead opting to go digital.
According to a study by KPMG Canada, 66% of Canadians increased their online shopping habits as a result of the pandemic. The 47% of Canadians who shifted to e-commerce do not miss their old way of grocery shopping, while only 15% of Canadians miss their old shopping habits and are eager to return to them (https://ibn.fm/4OX3F). The overall result was that online retail as a share of total retail sales grew from 3.6% in 2019 to 6.2% in 2020 (https://ibn.fm/cqWnH). These trends benefited some e-commerce stores, including Walmart Canada Marketplace, whose e-commerce sales grew by a staggering 229% during the pandemic.
In a deal that will allow it to leverage these trends/statistics, as well as Walmart Canada Marketplace’s extensive digital marketing services and customer base, PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) launched as a seller on Walmart Canada Marketplace, fulfilling a June 1 announcement. As part of the new collaboration, PlantX will make available for sell plant-based household supplies and pantry items from various brands, including Made in Nature, Cadia, Chickapea, NuNaturals, Fody, Plant Snacks, and Quantum, with potential opportunities to diversify its offerings on the platform in future (https://ibn.fm/vQ9xo).
“We have been focused on executing our growth strategy and our products being added to Walmart Marketplace is another component of expansion efforts,” commented PlantX Founder Sean Dollinger. “With our profile as a seller on this platform now active, we are excited to continue expanding access to our products to customers in Canada.”
In the June 1 communique (https://ibn.fm/fiph1), Dollinger had stated that the collaboration demonstrates the demand for PlantX’s products and “redefines PlantX’s potential as a plant-based leader.”
The Walmart Canada Marketplace announcement followed on the heels of a May 25 announcement that PlantX had launched as a seller on Hudson’s Bay Marketplace, a diversified retailer. While browsing the online store, customers can expect to find an assortment of indoor live plants, Nootka & Sea’s cosmetics and personal care products, and plant-based pet food from brands such as Evolution Diet and Benevo. Eventually, PlantX intends to offer more than 2,000 products on this online marketplace (https://ibn.fm/F2AfQ). “Witnessing our agreement with Hudson’s Bay Marketplace come to life is beyond encouraging,” stated PlantX CEO Julia Frank. “We hope practical ramifications of these efforts will be tangible, and we are looking forward to working with Hudson’s Bay Marketplace.”
With the majority of Canadians having already shifted to online shopping and an equally large proportion stating that they will continue going down that road well into the future, PlantX strategic partnerships appear to be capitalizing on the changes and emerging trends in the food and beverage industry.
Vancouver-based PlantX Life is a high-growth technology company focused on consumer-packaged goods (“CPG”) for the plant-based community. The company is committed to educating and empowering those interested in a plant-based lifestyle. “Shop with confidence at Plant X,” reads the company’s website. “We’ve done the work for you and everything we endorse meets our guideline for personal health and wellness morals. If it isn’t plant-based, we don’t offer it.”
For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://Investor.PlantX.com/ and view PlantX for Plant-Based Investors.
To visit the company’s YouTube channel, click here (https://ibn.fm/XiCLc).
NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
- FingerMotion’s strategy is to rapidly expand its user base through organic means utilizing a broad range of innovative applications
- It handles over 500,000 transactions every day for its mobile payment and recharge service, all facilitated by superior technology
- Technology and innovation are at the center of FingerMotion’s operations and activities and will clearly play a significant role in the company’s future
FingerMotion (OTCQX: FNGR), since its inception back in 2016, has always pushed boundaries with innovation and introducing new ideas. Innovation has always played a central role in what the company does, and it leverages this to expand its market reach and grow market share.
The company’s core competencies are mobile payments and recharge platform solutions for the Chinese market (https://ibn.fm/CSTyS). Today, it serves over a billion users in this market, intending to expand to other regions in the future. In 2021 alone, the company has introduced innovative insurance applications collaborating with Xunlian Tanxia Technology and Happy Life Insurance (https://ibn.fm/XIUKB). This innovation trend extends onto its other product offerings that fall into three main categories: Telecommunications Products and Services, SMS and MMS Services, Big Data Insights, and the Rich Communication Services (“RCS”) platform.
FingerMotion’s vision is to continue growing its user base, mainly through organic means. It also seeks to leverage this growth and transform it into an ecosystem of users with high engagement rates while utilizing its broad range of innovative applications (https://ibn.fm/w2wNR).
So far, the company handles over 500,000 transactions every day for its mobile payment and recharge service (https://ibn.fm/rgfus). These milestones have been achieved through the company’s technology and innovation, and the company seeks to develop further value-added technologies targeting its customer base.
FingerMotion’s innovation cuts across its four pillars of growth. These include its flourishing SMS business, strong top-up, mobile recharge business, emerging portal sales, and Insuretech space (https://ibn.fm/pngrc). The company has made incredible strides, with key achievements and milestones that include the launch of its Sapientus offering that capitalizes on big data and market-forming technology. Additionally, FingerMotion has also been responsible for launching business with the three key eCommerce portals in China – JD.com, PinDuoDuo and Alibaba (https://ibn.fm/E1szq).
Additionally, the two are intended to play a vital role in the company’s future, especially regarding taking over the Chinese market and expanding to other regions. Also, the company has been very vocal about outpacing changes in technology, which is integral given how fast technology is changing and the potential that it holds in FingerMotion’s market.
Technology affects how people learn, think, communicate, conduct business, or even interact with each other. FingerMotion’s move to bank on technology leverages the potential that it has and a consumer base committed to utilizing technology to make their lives easier.
For more information, visit the company’s website at www.FingerMotion.com.
NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR
About ChineseWire
ChineseWire (CW) is a specialized communications platform focused on promising China-based companies that are listed in North America. As one of 40+ brands within the InvestorBrandNetwork (“IBN”), CW provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution to IBN’s millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, CW is uniquely positioned to best serve private and public Chinese companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CW brings its clients unparalleled visibility, recognition and brand awareness. CW is where news, content and information converge.
For more information, please visit https://www.ChineseWire.com
Please see full terms of use and disclaimers on the ChineseWire website applicable to all content provided by CW, wherever published or re-published: http://IBN.fm/Disclaimer
ChineseWire (CW)
Los Angeles, California
www.ChineseWire.com
310.299.1717 Office
Editor@ChineseWire.com
ChineseWire is part of the InvestorBrandNetwork.
Last week, Neo Performance and Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) created a new U.S.-Europe supply chain for rare earth minerals when the first shipment of 20 tons of rare earth carbonate was shipped to Neo’s rare earth separation facility from the latter company’s production White Mesa Mill in Utah.
Energy Fuels expects to send out more shipments as it processes more of the monazite sand ore for the uranium and rare earth minerals it contains. The sand ore is mined by Chemours in its Georgia operations.
Rare earth elements are crucial elements needed for various advanced technologies and clean energy applications, advanced optics, wind turbines, medicine, catalysts, computers, cell phones, electric cars and national defense applications.
Monazite also holds considerable recoverable quantities of uranium, which is used in the production of carbon-free electricity through the use of nuclear technology.
The United States has been heavily reliant on China for its rare earth metals. This has been highlighted in the tensions between the two countries, which may hinder the U.S. from importing more of the critical mineral from China.
At the moment, Energy Fuels is the only company in the U.S. moving the commodity, despite the presence of other miners of rare earth minerals in the market that are occupied with permitting processes or sample testing in laboratories.
During an interview, Energy Fuels CEO Mark Calmers stated that projections showed that in the next decade, the demand for rare earth minerals would grow fivefold, noting that the company was making significant progress in comparison with other companies in North America. Chalmers added that the lack of a separation facility in America was what prompted the company to enter into a contract with Neo Performance Materials, which is the sole European manufacturer of separated rare earth oxides.
To begin with, the recently created supply chain will manufacture rare earth commodities from monazite, which will be processed into rare earth carbonate at Energy’s Utah White Mesa Mill. The carbonate will then be transported to Neo Performance’s Silmet processing facility located in Estonia, where it will be separated into different compounds, among them being rare earth oxides.
Energy Fuels is planning on building a separation facility at White Mesa in the near future. It has hired Carester SAS, a French company that specializes in the field of engineering and technical studies, to produce a scoping study which will include operating costs and capital for a full rare earth separations plant at its mill.
NOTE TO INVESTORS: The latest news and updates relating to Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) are available in the company’s newsroom at http://ibn.fm/UUUU
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.MiningNewsWire.com
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com
MiningNewsWire is part of the InvestorBrandNetwork.
- CYBN subsidiary Adelia Therapeutics has reached earn-out milestones.
- Adelia’s earn-out milestones contributed to positive preclinical results with multiple proprietary psychedelic molecules.
- Cybin’s development of these compounds differentiates it from companies focused on naturally occurring psychedelic compounds.
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that earn-out milestones have been reached by its wholly controlled subsidiary Adelia Therapeutics Inc. These milestones, which were for the period commencing Jan. 1, 2021, add value to Cybin’s pipeline of novel psychedelic compounds (https://ibn.fm/Y1YPb).
“These positive catalysts continue to provide the necessary data required to demonstrate that Cybin’s proprietary deuterated psychedelic molecules potentially carry the same pharmacodynamic properties, safety profiles, potency and receptor targeting as their parent molecules,” said Cybin CEO Doug Drysdale. “While the profiles are similar to parent molecules, early research has shown that these proprietary molecules also carry certain characteristics that may lead them to potentially become commercially viable because of their improved stability, bioavailability, controlled psychedelic duration and overall enhanced chemical make-up.”
Adelia’s earn-out milestones contributed to positive preclinical results with multiple proprietary psychedelic molecules, the company reported. Those results determined that proprietary deuteration modifications in multiple-lead new chemical entity candidates did not alter pharmacodynamic properties and did not alter safety as assessed in in-vitro toxicity tests as compared to non-deuterated analogs. These promising results add value to the pipeline of proprietary novel psychedelic compounds that Cybin is developing.
The results, the company noted, demonstrate that “these molecules perform similarly to the naturally occurring molecules in certain important metrics. The development of these compounds differentiates Cybin from companies focused on naturally occurring psychedelic compounds.”
Cybin closed on its acquisition of Adelia in December 2020 in a move that Drysdale stated as “potentially advancing Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder.
“Adelia’s focuses on novel delivery methods and innovative therapies may contribute to our goal of therapies with faster onset of action, smoother pharmacokinetic profiles, shorter treatment periods and reduced side effects,” Drysdale continued. “Adelia’s expertise across multiple molecules and multiple indications could potentially give Cybin the ability to address gaps across a larger domain” (https://ibn.fm/XaFk4).
Cybin, a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
A recent study conducted by researchers from the Academy of Finland has found that almost half of all coronavirus patients who also suffer from obstructive sleep apnea need to be hospitalized. The study, which was reported in the BMJ journals, noted that moderate to acute sleep apnea predisposes individuals to acute coronavirus. Other coronavirus risk factors include older age, diabetes and a high body mass index.
The researchers used FinnGen data for their study, which was backed by the Center of Excellence in Complex Disease Genetics. The researchers linked data obtained from the Finland National Infectious Disease Register on coronavirus diagnosis with other health data, which they then used to identify more than 400 patients with coronavirus infections, 38 of whom also suffered from obstructive sleep apnea.
This led researchers to the discovery that, when compared with other individuals who had been infected with COVID-19, the latter group had a significantly higher risk of being hospitalized as a result of this fatal disease.
Many individuals who are infected with COVID-19 display no symptoms. This is proven in a follow-up study dubbed GeneRISK, which involved more than 7,000 participants from Finland’s Kotka region and Helsinki. Of the participants, an estimated 2,000 had been tested for SARS-CoV-2 virus antibodies while almost 3,000 had filled out a coronavirus symptom questionnaire at least once. The researchers found that only 1.5% and 2% of participants’ samples in the Kotka and Helsinki regions respectively showed the disease’s antibodies, noting that of this number, only a few reported that they’d experienced coronavirus symptoms.
Prof. Samuli Ripatti, the study’s lead who is also a part of the Institute for Molecular Medicine Finland, stated that the coronavirus pandemic had highlighted the importance of an infected individual’s genome and the virus’ genome to the ailment’s severity and the individual’s susceptibility to infection. He explained that analyzing the virus’ properties and its carriers as well as its interactions would be useful in helping researchers prepare for future pandemics, adding that the study enabled them to utilize already existing health data to study the severity of the coronavirus infection as well as susceptibility.
Together with an international team of researchers, Ripatti has identified areas in the human genome that are linked to higher susceptibility to infection with acute coronavirus. Researchers have also found that these genes are associated with severe pulmonary illnesses such as idiopathic lung fibrosis and lung cancer as well as autoimmune disease.
One way to prevent COVID-19 from becoming a severe infection is by early diagnosis and prompt treatment. The work of companies such as XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is helping in this regard as better PCR test kits that collapse the turnaround time from sample extraction to getting results are now being introduced on the market.
NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
LAS VEGAS and VANCOUVER, British Columbia, July 16, 2021 — TAAT ™ GLOBAL ALTERNATIVES INC. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) (the “Company” or “TAAT ™ ”) is pleased to provide updates relating to its new facilities in Las Vegas, Nevada. In a press release dated April 30, 2021 , TAAT™ announced that it had finalized a lease agreement for new facilities to expand the Company’s manufacturing and warehousing capacities. Combined with the Company’s existing facility at 4730 West Post Road (8,000 square feet / 743 square metres), the new facilities will considerably increase the Company’s total operating space and can allow for the creation of new internal departments for purposes such as digital content production and event management. To preserve the Company’s inspection workflows and laboratory setups, the TAAT™ quality assurance department will remain at the West Post Road office.
With new domestic launches of TAAT™ in motion and fulfillment underway for the Company’s first international order to a distributor in the United Kingdom, this facility expansion is a proactive effort to ensure the Company has sufficient capacity to meet foreseeable demand. In just nine months on the market, TAAT™ has been placed in over 300 U.S. retail stores, and cartons of TAAT™ have been shipped to smokers aged 21+ in a total of 37 states through e-commerce sales. Although its existing facility can produce enough base material for approximately 680,000 ten-pack cartons of TAAT™ per year, the Company believes it to be prudent to increase this manufacturing bandwidth as product launches are occurring in new markets.
Since the initial announcement of this expansion, milestones and material events in preparation for beginning operations in the new facilities include the following:
All Processing Equipment Successfully Moved into New Manufacturing Facility
As of mid-July 2021, all machinery for processing Beyond Tobacco™ ( e.g. , mixers, shredders, conveyor belts) has been moved into the new manufacturing facility. In the coming weeks, additional machinery (including existing “finishing” equipment as well as new machines arriving from overseas vendors) will also be moved according to a timeline in which the new manufacturing facility will start operating in August 2021.
Upgraded Storage Space for Beyond Tobacco™ Base Material
In the Company’s new warehouse facility, it will be possible to store approximately 400,000 lb / 181,400 kg of the Beyond Tobacco™ base material (compared to approximately 150,000 lb / 68,000 kg at the current facility) after it is finished and awaiting shipment to a contract cigarette manufacturing partner. In addition to standard climate controls, this storage space also has humidity control functionality which can be used to keep the base material fresh, thereby extending its shelf life.
Fulfillment Station More than Triples in Size
To efficiently facilitate the fulfillment of direct-to-consumer e-commerce orders as well as wholesale purchase orders of finished TAAT™ products, the fulfillment station at the Company’s new warehouse will be over 200% larger than its current size in the West Post Road facility. The new fulfillment station will also have four loading doors at “dock height”, which can reduce pickup and drop-off times for logistics providers. The Company is also evaluating technologies and solutions which could further optimize in-house order fulfillment with this additional space.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a794b724-5bdf-4ae0-bdf2-06f5a146bfd8
The entrance doors to the Company’s new facilities now bear brand insignia to include the TAAT™ logo as well as the Beyond Nicotine™ slogan, which the Company recently began using in support of impending federal anti-nicotine regulations from the Biden Administration in the United States
Readers using news aggregation services may be unable to view the media above. Please access SEDAR or the Investor Relations section of the Company’s website for a version of this press release containing all published media.
TAAT™ Chief Executive Officer Setti Coscarella commented, “Expanding and upgrading the Company’s operating facilities after barely three calendar quarters of selling TAAT™ at retail is an excellent indicator of our progress in my opinion. At this time last year, I was still at Philip Morris International and TAAT™ was still offering ‘test’ iterations of the product to smokers aged 21+ in Nevada and California. Now that we have tobacco wholesalers in multiple markets distributing TAAT™ to more than 300 retail stores in addition to an e-commerce pipeline with clientele in 37 U.S. states, I believe it goes without saying that we could not continue operating out of the same facility if we’re looking to continue scaling our business. Everything is looking great so far, and we are excited to be making this expansion official in August, giving us the room we need to grow as an emerging player in the tobacco industry.”
On behalf of the Board of Directors of the Company,
TAAT ™ GLOBAL ALTERNATIVES INC.
“Setti Coscarella”
Setti Coscarella, CEO and Director
For further information, please contact:
TAAT™ Investor Relations
1-833-TAAT-USA (1-833-822-8872)
investor@taatusa.com
THE CANADIAN SECURITIES EXCHANGE (“CSE”) HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE, NOR HAS OR DOES THE CSE’S REGULATION SERVICES PROVIDER.
About TAAT ™ Global Alternatives Inc.
The Company has developed TAAT™, which is a tobacco-free and nicotine-free alternative to traditional cigarettes offered in “Original”, “Smooth”, and “Menthol” varieties. TAAT™’s base material is Beyond Tobacco™, a proprietary blend which undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco. Under executive leadership with “Big Tobacco” pedigree, TAAT™ was launched first in the United States in Q4 2020 as the Company seeks to position itself in the $814 billion 1 global tobacco industry.
For more information, please visit http://taatglobal.com .
References
1 British American Tobacco – The Global Market
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking information and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur, or be achieved. Forward-looking information in this news release includes statements regarding the anticipated performance of TAAT™ in the tobacco industry, in addition to the following: The successful setup, launch, and operation of the Company’s new facilities and potential corresponding effect of the same on the Company’s performance. The forward-looking information reflects management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking information. Although the Company believes that the assumptions and factors used in preparing the forward-looking information are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed timeframes or at all. Factors that could cause actual results or events to differ materially from current expectations include: (i) adverse market conditions; (ii) changes to the growth and size of the tobacco markets; and (iii) other factors beyond the control of the Company. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking information. The forward-looking information included in this news release are made as of the date of this news release and the Company expressly disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law.
The statements in this news release have not been evaluated by Health Canada or the U.S. Food and Drug Administration. As each individual is different, the benefits, if any, of taking the Company’s products will vary from person to person. No claims or guarantees can be made as to the effects of the Company’s products on an individual’s health and well-being. The Company’s products are not intended to diagnose, treat, cure, or prevent any disease.
This news release may contain trademarked names of third-party entities (or their respective offerings with trademarked names) typically in reference to (i) relationships had by the Company with such third-party entities as referred to in this release and/or (ii) client/vendor/service provider parties whose relationship with the Company is/are referred to in this release. All rights to such trademarks are reserved by their respective owners or licensees.
Statement Regarding Third-Party Investor Relations Firms
Disclosures relating to investor relations firms retained by TAAT™ Global Alternatives Inc. can be found under the Company’s profile on http://sedar.com .
Phoenix, Arizona–(July 16, 2021) – The Stock Day Podcast welcomed Pressure BioSciences, Inc. (OTCQB: PBIO) (“the Company”), a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. President and CEO of the Company, Mr. Richard Schumacher, joined Stock Day host Everett Jolly.
Mr. Schumacher began the interview by elaborating on a recent press release detailing the Company’s ability to transform the potent antioxidant Astaxanthin into a water-soluble compound: “Antioxidants have become one of the hottest topics in nutrition and health over the past 20 years, and Astaxanthin is the most powerful nutritional antioxidant known to humans. It is not just an antioxidant but offers many other very positive qualities for people that take it as a supplement. It is an oily molecule that is produced in algae, which is eaten by krill, and then the krill is eaten by salmon, which is what gives them that beautiful pink to red coloration that we associate with their rich taste and healthiness. It similarly adds color to many other things, from crayfish to flamingos.”
Mr. Schumacher continued: “Astaxanthin is in short supply and is not easy to obtain. It is extracted from algae in an oil, just like CBD is extracted from plants in an oil, and like Omega-3 fatty acids are obtained from fish and plant oils. So many important nutrients are oily molecules delivered in oils, but humans, animals and plants are primarily water-based, as you know, and the natural resistance of oil and water to mix presents obvious challenges to our body’s ability to absorb oil-based nutrients. The solution lies in finding ways to get them to mix and stay in solution – but even conventional emulsions and microemulsions of oils in water still allow vast numbers of the oil molecules to hide in the interior of the droplets, where they cannot be absorbed by our bodies. However, using Pressure BioSciences’ new high-pressure driven Ultra Sheer Technology™ (UST™) platform, we were able to consistently and reproducibly nanoemulsify it into droplets so small that the oil becomes essentially water-soluble, and the oily molecules are effectively all exposed at the surface of the oil droplet for easy access and absorption by our bodies.”
Mr. Schumacher elaborated further on the process of the Company’s Ultra Sheer Technology platform: “The starting emulsion oil drops are each sheared into maybe a million tiny oil droplets, so small that the resulting nanoemulsions are transformed from cloudy to transparent (no longer scattering light), but the oily active ingredient molecules inside of the droplets are not changed. In the nanoemulsion, the oily molecules are presented to our bodies over much more surface area, so that when you ingest it or apply it topically, your body can be vastly more effective at being able to absorb and benefit from the active ingredient, in this case Astaxanthin.”
Mr. Jolly then asked: “How are you going to sell this?”
Mr. Schumacher responded: “We are a specialty equipment company. We make equipment that harnesses high pressure to perform astonishing transformations in all sorts of materials and samples; we are one of the few companies in the world who has learned how to safely commercialize high-pressure chambers and processing. However, our unique difference is that our instruments and equipment operate at much higher pressures than the few other companies that have tried to work in the high-pressure arena, and we have patented a remarkably innovative dynamic valve design and other special components and consumables within the Ultra Sheer Technology platform that make this platform remarkably robust and reproducible in producing the highest-quality nanoemulsions.”
Mr. Schumacher continued: “We have decided that the optimal path for commercializing our UST nanoemulsions platform is to lease out the equipment with service support, and a royalty participation structure. This strategy allows our customers to engage and grow with a low initial financial commitment, while allowing us to scale our profitability alongside our customer’s success.”
Mr. Jolly then asked about the Company’s CBD stability achievement news: “Please explain the significance of this, and where you are in that process.”
Mr. Schumacher responded: “As I mentioned, if the consumer’s body cannot pull the nutrient out of the oil droplet, it will not benefit them. Experience has shown in CBD’s case that it is even more difficult to effectively extract and absorb CBD in our bodies than for Astaxanthin. We also know that there are multiple papers that have been published from academic, government, and industry sources showing that (if you have not produced a high-quality nanoemulsion) the macro- and micro-emulsions of CBD that are generally available today contain much larger droplets of oil containing CBD, with the result that the amount of CBD that your body can absorb out of that ingested oil before it is excreted is typically less than 10%.”
Mr. Schumacher continued: “How do we solve that problem? The same way that we fixed it with Astaxanthin, and the same way we will fix it with vitamin D and with any other oil-based nutrient or therapeutic that are not normally easily absorbed by human beings or animals due to their water-based biochemistry: we use our UST processing to make it into the highest quality, consistent and reliable nanoemulsion available in the world today.”
Mr. Schumacher then announced: “Fourteen months ago, we used our system to make a nanoemulsion of CBD oil and water, and the CBD disappeared into the water, becoming transparent as it should. We put it on the shelf in the refrigerator and on the shelf in the lab for those fourteen months. Our goal was to see if there was any possibility that our breakthrough nanoemulsion processing technology could achieve long term shelf stability, maybe even up to twelve months of stability – something that we believe no other nanoemulsion technology has achieved today short of employing undesirable chemicals. Well, we have soared past twelve months, and there is no significant measurable change in the CBD nanoemulsion at either temperature or even after repeated freeze/thaw cycles.”
Mr. Jolly asked: “What is the progress with the plan to commercialize the Ultra Sheer Technology (UST) platform?”
Mr. Schumacher shared: “All of this is coming from our UST demonstration platforms. Some highlights of our progress include that we have now been issued six new patents on our Ultra Shear Technology, including one in the United States, and we are confident that more will be coming soon. We are still looking to the end of the year as the timing for launch and placement of our first commercial UST instruments. We are also talking to CBD companies, Astaxanthin companies, and a lot of companies that deal with oil-based nutrients, vitamins, supplements, and other products.
Mr. Schumacher expanded: “We would like to have our first batch of instruments for our leasing and royalty-driven business model available by the end of the year, so that we start 2022 with instruments in place for production in customer facilities. We have struggled through a long period as a small and undercapitalized company, but the message of our UST opportunity is getting out to our diverse prospective customer base, and our outlook has been improving rapidly. We are feeling pretty optimistic that we can meet our goal of having the first set of instruments, maybe a dozen of them, being placed in customer facilities by the end of the year.”
Mr. Schumacher then elaborated on the Company’s collaboration with Ohio State University, an institution that is home to some of the nation’s leading experts in nanoemulsions in food applications: “We have set up a food industry consortium with them, to facilitate demonstrations, early access and scaling studies on an industrial scale prototype of our UST processing equipment, for all kinds of beverage and liquid food applications. We believe that a number of the well-known beverage brand companies in the world, as well as some new age beverage companies, will become members of this unique early access consortium. This will get the first looks and trials with our industrial-scale prototype, which we will be installing at Ohio State University in the next couple of months.”
Mr. Schumacher then closed the interview: “We believe we are a company with an incredible future. We have built this transformational opportunity, for us and for partners and consumers around the world, very patiently and with a focus on quality and robustness. Our UST technology is unique and indeed transformational for enormous and diverse markets worldwide. We have very smart and hardworking people, and our team is very excited about what we and our partners will be accomplishing together in the coming months. It has been hampered to date by a lack of capital, but the recent solidification of market and investor understanding and the resulting strength still building in our stock has been generating a deluge of phone calls from investors – and we are very excited to now be on the path to achieving all that we have been planning for past few years.”
To hear Mr. Richard Schumacher’s entire interview, follow the link to the podcast here: https://audioboom.com/posts/7906519-pressure-biosciences-inc-discusses-historic-cbd-nanoemulsion-stability-achievement-and-astaxant
Investors Hangout is a proud sponsor of “Stock Day,” and Stock Day Media encourages listeners to visit the company’s message board at https://investorshangout.com/.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
For more information about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.com
Press Contacts:
Richard T. Schumacher, President & CEO (508) 230-1828 (T)
Jeffrey N. Peterson, Chairman (650)703-8557 (T)
Alexander V. Lazarev, Chief Science Officer (508) 230-1828 (T)
About The “Stock Day” Podcast
Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.
SOURCE:
Stock Day Media
(602) 821-1102
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is leveraging its unique, historical database of the drug responses of over 150,000 patient tumors to build data-driven predictive models of tumor drug response. These models will provide actionable insights critical to both new drug development and individualizing patient treatment. “While others must wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine,” a recent article reads. “Predictive Oncology presently has the clinical information, including tumor drug response data and an in-house bioinformatics AI platform.” POAI has an impressive portfolio, spanning four different subsidiaries — Helomics, TumorGenesis, Soluble Biotech, and Skyline Medical — and including a list of assets that rivals the best operators in the space. “This strong portfolio makes POAI a strong standout in precision medicine, where precisely targeting drugs on the genomic profile of the patient’s tumor has become the aspiration for cancer therapy.”
To view the full article, visit: https://ibn.fm/BebF1
About Predictive Oncology Inc.
Predictive Oncology operates through three segments (Skyline, Helomics, and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical, and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins, including vaccines, antibodies, large and small proteins, and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Most developed countries are hoping for electric vehicle (“EV”) sales to surpass the sale of internal combustion engine (“ICE”) vehicles over the next couple of decades. The United States, China and Europe are currently the largest EV markets in the world, but save for Norway and Southern Chinese city Liuzhou, EV sales in most territories make up a small percentage of total vehicle sales. As such, most of these countries have given themselves years, and in some cases decades, to slowly replace ICE vehicles with zero-emission electric cars.
However, new research from Ernst & Young says that these counties may not have to wait dozens of years for electric vehicles to dominate their roads. According to the consultancy firm, electric vehicle sales in the U.S., China and Europe will surpass other engine models five years sooner than previous predictions had stated. Ernst & Young arrived at this conclusion using an AI-powered forecast modeling tool that can predict how the supply and demand of mobility products and services will evolve through to 2050.
The AI-powered tool found that EV sales would surpass the sale of vehicles powered by other engines by 2033 in the three territories. Specifically, Europe would be the first to achieve this feat, with EV sales in the regional block eclipsing other engine modules in 2028. China would follow in 2033, and the United States would see major EV sales by the year 2036. By 2045, the sale of new nonelectric vehicles will shrink to less than 1% of total vehicle sales, the modeling predicts.
It is not surprising that Europe, which has increasingly led the way in terms of technological growth innovation and growth for the past decade, and even briefly passed China to become the largest EV market, will achieve this feat first. After that, China will take the top spot in terms of EV penetration, leading the charge through 2050. Randall Miller, the Global Advanced Manufacturing & Mobility Leader at EY, credits changing attitudes among consumers, continually evolving technology, and ambitious climate and green energy policies with pushing EV adoption.
To support a mass shift toward electric vehicles, he says, government and energy industries will have to significantly boost their electricity generation capabilities and vastly improve charging infrastructure. With an electric future coming much sooner than expected, investing in energy generation, especially from clean, renewable sources, and building a widespread network of charging networks will help smooth the transition.
The task of enabling motorists to switch to electric mobility is also being aided by new entrants into the EV space such as Net Element (NASDAQ: NETE). These players bring technologies and solutions adapted from other industries.
NOTE TO INVESTORS: The latest news and updates relating to Net Element (NASDAQ: NETE) are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
Infobird (NASDAQ: IFBD), a business-to-business (“B2B”) artificial intelligence (“AI”) solutions company, recently announced its platform would provide Zu Li Jian, a pioneer in the production of footwear for the elderly in China, with cloud-native, autonomous and controllable source code resources to create flexible customization and expansion for Zu Li Jian’s own e-shopping platform. Through IFBD’s upgrade, Zu Li Jian’s customer service platform will now boast high stability, high concurrency and high expansion capability, making it responsive to future needs and business peaks. “The announcement follows on the heels of a similar intelligent B2B collaboration that will deliver enhanced customer service and marketing capabilities to beauty retail services company SaSa Cosmetics (China) Co. Ltd,” reads a recent article. “Together, these latest agreements provide validation that Infobird’s SaaS products have successfully entered the retail industry and are gaining recognition from reputable large enterprises.”
To view the full article, visit https://ibn.fm/IZD1C
About Infobird Software Co. Ltd.
Infobird, headquartered in Beijing, China, is a software-as-a-service (“Saas”) provider of innovative AI-powered or enabled customer engagement solutions. For more information about the company, visit www.Infobird.com.
NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at http://ibn.fm/IFBD
About ChineseWire
ChineseWire (CW) is a specialized communications platform focused on promising China-based companies that are listed in North America. As one of 40+ brands within the InvestorBrandNetwork (“IBN”), CW provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution to IBN’s millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, CW is uniquely positioned to best serve private and public Chinese companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CW brings its clients unparalleled visibility, recognition and brand awareness. CW is where news, content and information converge.
For more information, please visit https://www.ChineseWire.com
Please see full terms of use and disclaimers on the ChineseWire website applicable to all content provided by CW, wherever published or re-published: https://www.ChineseWire.com/Disclaimer
ChineseWire
Los Angeles, California
www.ChineseWire.com
310.299.1717 Office
Editor@ChineseWire.com
ChineseWire is part of the InvestorBrandNetwork.
Ideanomics (NASDAQ: IDEX), a global company focused on driving the adoption of commercial electric vehicles and associated energy consumption, will be hosting an earnings call and webcast. The event, which is scheduled for Aug. 16, 2021, will focus on the company’s second-quarter financial results, which will be released that same day at 4 p.m. ET; the conference call will begin at 4:30 p.m. ET. During the call, Ideanomics executives will present key information. The call will also have time set aside for a Q&A session. Interested parties can participate on the call by dialing toll free in Canada and the United States using 877-407-3107 or 201-493-6796. In addition, a replay will be available on the company’s investor relations website following the call.
To view the webcast, visit https://ibn.fm/OaQXj
To view the full press release, visit https://ibn.fm/YwTQi
About Ideanomics Inc.
Ideanomics is a global company focused on the convergence of financial services and industries experiencing technological disruption. The Ideanomics Mobility division is a service provider that facilitates the adoption of electric vehicles by commercial fleet operators through offering vehicle procurement, finance and leasing, and energy-management solutions under the company’s innovative sales-to-financing-to-charging (“S2F2C”) business model. Ideanomics Capital is focused on disruptive fintech solutions for the financial services industry. Together, Ideanomics Mobility and Ideanomics Capital provide the company’s global customers and partners with leading technologies and services designed to improve transparency, efficiency and accountability, and the company’s shareholders with the opportunity to participate in high-potential, growth industries. For more information about the company, please visit www.Ideanomics.com.
NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at http://ibn.fm/IDEX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
FingerMotion (OTCQX: FNGR), a mobile services and data company, has reported its financial results for the first quarter 2021, ended May 31, 2021, and filed the full report with the U.S. Securities and Exchange Commission. Key highlights of the report include record quarterly revenue totaling $6 million, including the company’s SMS & MMS texting service, telecommunications products and services, and big data business; 77% quarterly growth in the SMS & MMS business revenue, which reached $1.81 million; and growth of more than 300% in the company’s telecommunications products and services business, which totaled $1.34 million. The company’s big data business also grew, increasing nearly 200% with reported revenues of $98,715. “The first quarter generated $6 million in revenue and represented the fourth consecutive quarter of record revenue,” said FingerMotion CEO Martin Shen in the press release. “If the current trajectory continues, revenue may exceed $24 million for FYE 2022. Growth continues to be fueled by an expansion of subscribers in new regions along with larger purchases of SMS from our corporate clientele. This is the second consecutive quarter of big data revenues, and we expect it to continue and eventually outpace our existing revenue streams. . . . We are pleased to announce that the company completed the first stage of prototyping of its insurtech model and expects completion by the end of this calendar year.”
To view the full press release, visit https://ibn.fm/ER9RS
About FingerMotion Inc.
FingerMotion is an evolving technology company with a core competency in mobile payment and recharge platform solutions in China. As the user base of its primary business continues to grow, the company is developing additional value-added technologies to market to its users. The vision of the company is to rapidly grow the user base through organic means and have this growth develop into an ecosystem of users with high engagement rates utilizing its innovative applications. Developing a highly engaged ecosystem of users would strategically position the company to onboard larger customer bases. FingerMotion eventually hopes to serve more than 1 billion users in the China market and eventually expand the model to other regional markets. For more information about the company, please visit www.FingerMotion.com.
NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at http://ibn.fm/FNGR
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Research has found that psychedelics possess therapeutic benefits that can be used to manage various mental health conditions, including anxiety and depression. Until recently, most studies conducted on these substances had been small scale. The Global Ayahuasca Project, which focused on ayahuasca, is the largest cross-sectional study on the use of ayahuasca to date.
Ayahuasca is a pan-Amazonian (South American) psychedelic brew made from the Banisteriopsis caapi vine, which is utilized in ceremonial spiritual medicine as well as socially.
The study, which was carried out between 2017–2020, found a connection between improvements in the symptoms of disorders such as depression and the use of ayahuasca. Its findings were reported in the “Journal of Affective Disorders Reports” in April of this year.
For the study, the researchers recruited more than 11,000 participants. Of this number, almost 8,000 reported that they suffered from symptoms of anxiety or depression before the substance was administered. The researchers utilized various methods to evaluate the subjective experience of each participant during and after the experience, as well as the mental health outcomes of each one of them. The study’s results demonstrate tremendous improvements in symptoms of anxiety and depression in more than 90% of the participants who suffered from both disorders.
The presence of a large sample size enabled the researchers to draw various conclusions about the ayahuasca experiences that corresponded with significant improvements, noting that individuals who had undergone profound mystical experiences were more likely to see greater improvements. Greater insights into an individual’s personal relationships also corresponded strongly with improvements, which suggests a cognitive pathway through which the substance may alleviate symptoms of depression and anxiety.
In their report, the researchers stated that approximately 4% and 3% of participants who suffered from anxiety and depression respectively, reported that their symptoms worsened, adding that feelings of hopelessness, depression, being on edge, nervous, lonely or disconnection were used as predictors of worsening symptoms.
The team also noted that the study had some limitations, the primary one being its cross-sectional nature, which meant that the researchers couldn’t accurately confirm the presence of a causal relationship. The unreliability of affective, historical self-reporting was also another limitation of the study.
All in all, the research proposes an important association between improved symptoms of individuals who suffer from anxiety and depression and the use of ayahuasca. The researchers assert that understanding the social, emotional and cognitive pathways by which psychedelics such as ayahuasca work is critical.
The quest to understand these substances and how they can be safely used as therapeutics has led numerous companies, including Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF), to conduct various research and development activities, many of which have progressed to the stage of clinical trials.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
- Scientific evidence is mounting that SARS-CoV-2 can cause neurological damage in patients hospitalized with the infection.
- A recent study that appeared in the journal JAMA Network Open finds five times increased mortality risk in patients hospitalized with COVID-19, citing encephalopathy as the most common neurological disease found in the clinical setting.
- As more research is needed to understand how COVID-19 affects the brain, Brain Scientific appears poised to offer technology solutions as a leading player in the neurological diagnostics space.
As the world learns more about the novel SARS-CoV-2 virus, the evidence about neurological symptoms developed by patients who suffered from COVID-19 is mounting, and the market for Brain Scientific’s (OTCQB: BRSF) innovative products appears to expand. A recent article published in Medical News Today discusses findings of the observational study examining neurological issues in patients hospitalized with COVID-19. The research which appeared in the journal JAMA Network Open unveils that the most prevalent neurological symptom observed in the clinical setting was acute encephalopathy also finding a relationship between neurological issues and a higher risk of dying in the hospital in patients infected with the SARS-CoV-2 virus (https://ibn.fm/j0F22).
Although COVID-19 is considered a respiratory disease that mainly affects patients’ pulmonary systems, research is increasingly documenting that the disease can affect many other organs and systems, including the brain. Since the start of the pandemic, it has been observed in a clinical setting that some patients with COVID-19 have also developed neurological symptoms. However, more than a year into the pandemic, medical professionals and scientists alike still do not fully understand the prevalence of neurological problems or their relationship with mortality risk.
To help fill this literature gap, Dr. Sherry Chou and her research team from the University of Pittsburgh School of Medicine performed an interim analysis of patient data collected from two large global consortia involving 3,744 patients across three cohorts. The study’s goal was to examine the incidence, type and outcomes of neurological manifestations among patients hospitalized with COVID-19.
What data revealed was astonishing. The first cohort involving 3,055 patients hospitalized with COVID-19, both with and without neurological symptoms, unveiled that the most prevalent clinically reported neurological sign was acute encephalopathy, found in 50% of patients, while the most frequent self-reported symptom was headache (38%), and the loss of taste or smell (28%). The second and third cohorts involving patients with confirmed neurological issues and those who had received a neurological consultation also show encephalopathy as the most common neurological issue (53% and 24%, respectively). Again, it was followed by headaches and the loss of taste and smell as the most common self-reporting neurological symptoms.
Research also reveals that if a patient has neurological issues resulting from COVID-19, it increases their risk of dying while in hospital by five times. Authors suggest that a formal neurological consultation may be needed in cases where doctors suspect neurological symptoms in individuals testing positive for COVID-19.
Although an association between neurological issues in COVID-19 patients and an increased risk of in-hospital mortality has been established, more research is needed to identify if these neurological symptoms are causing the increase in mortality. Notwithstanding some practical limitations of the study, it lays the groundwork for future research involving standardized protocols, which may be able to track patients with neurological issues after they leave the hospital.
As we learn more about the novel SARS-CoV-2 virus, it is becoming increasingly clear that neurological diagnostics will be at the center of the future post-COVID-19 health care of patients who suffered from the infection. Dr. Chou, the lead author of the study, emphasizes that even if we eradicate the pandemic, there are already millions of survivors who need neurological help, and there is still plenty of work in years to come.
As a commercial-stage health care company focused on developing innovative medical devices and software disrupting the brain diagnostics market, Brain Scientific is poised to be at the center stage of neurological diagnostics space offering solutions for this growing public health problem with its two commercialized and FDA-cleared devices, NeuroCap(TM) and NeuroEEG(TM). Committed to a vision to allow medical professionals to conduct brain activity studies and collect diagnostic information more quickly, Brain Scientific appears well-positioned to offer solutions for the growing market need in the post-pandemic world.
For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
As more states across the country legalize and decriminalize marijuana for medical and recreational use, the burgeoning industry continues to grow. This, as well as the different ways CBD and THC, which are compounds of marijuana, can be consumed, has made it possible for the manufacture of marijuana products that cater to different consumer needs.
Below are a few of the marijuana products that are gaining popularity as the fight to end the plant’s federal prohibition continues.
Gummies
For consumers who are fans of sweet stuff, CBD gummies may be the perfect option. While it may be challenging to accurately determine the amount of CBD present in the gummies, this doesn’t seem to impact either their popularity or their ease of access.
Lots of companies make gummies containing either CBD or THC alone, depending on the laws in the states in which they are operating.
Cannabis beverages
A recent article on CBD cocktails found that marijuana beverages were gaining more exposure, which only increased their popularity. The legalization of the herb for recreational use may also help move things along. Such progress can be seen in states such as Colorado, where recreational cannabis is legal. Some dispensaries in the state sell marijuana fruit punch and cola.
Over in New York, various coffee shops also offer marijuana-infused coffees, which are said to be perfect for calming one’s nerves. Additionally, Coalition Brewing’s CBD-infused beer is available at various locations in the states of Washington and Oregon, with the company that created Blue Moon currently working to also develop nonalcoholic marijuana-infused beers.
Cannabis skin care and beauty products
CBD is said to possess many beneficial properties, among them anti-inflammatory properties, which some scientists say may help combat acne. Beauty products that contain CBD have become so popular that some can be purchased from the Sephora website.
The CBD topicals market continues expanding as more products containing CBD, such as bath salts and bath bombs, balms, mascara, lip gloss and body wash, are introduced to the market. One should keep in mind that the cannabinoid type in the beauty product determines its effects.
CBD oil
Cannabis oils have low THC amounts and can be used to relieve nausea and anxiety, as well as alleviate pain, without inducing any psychoactive reactions.
The oil has also been used in the production of a pharmaceutical formulation indicated for the treatment of some forms of epilepsy. This treatment (Epidiolex) was recently approved by the U.S. FDA.
In addition to this, cannabis oil has also demonstrated that it can be useful in combating sleep issues, depression, and anxiety as well as being considered as a complementary cancer treatment.
For users who are looking to try legal cannabis but aren’t big fans of smoking, the above options afford a bevy of products to choose from. However, it is important to remember that marijuana is still illegal at the federal level, so users should be mindful to now break any laws in the state in which they are indulging.
CBD-infused products are in such high demand that established companies such as The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) have an entire line of CBD-infused products, including salves, gummies, infused drinks, lotions and balms among others.
NOTE TO INVESTORS: The latest news and updates relating to The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) are available in the company’s newsroom at http://cnw.fm/WTER
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
Pressure BioSciences (OTCQB: PBIO) (“PBI”) is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and platform technology solutions to the worldwide biotechnology and other industries. The company has announced that its founder, president and CEO Ric Schumacher appeared as an invited guest on Tuesday, July 13, on the internationally acclaimed Power Hour luncheon hosted by Benzinga. Schumacher joined the podcast interview to provide a short overview of the company as well as to discuss two exciting announcements that PBI released over the past week. The announcements covered Pressure BioSciences’ Ultra Shear Technology- (“UST”) enabled nanoemulsions soaring past the one-year stability goal, opening explosive growth potential for water-soluble CBD-infused beverages worldwide, as well as the company’s UST platform delivering breakthrough nanoemulsion processing for Astaxanthin – one of the world’s most potent antioxidants.
To watch the interview, visit https://ibn.fm/LZSiY
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). The company’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) recently acquired, patented technology from BaroFold Inc. (the BaroFold technology) to allow entry into the bio-pharma contract services sector, and (2) recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information about the company, visit www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
